

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079US

SERIAL NO.: 09/154,354

10/057,632

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998

GROUP: 1627 1639

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
													YES	NO
	AA	0	6	5	4	2	6	3	05/24/95	EP (A1)	A61K	31/135		
	AB	0	6	5	4	2	6	3	05/24/95	EP (B1)	A61K	31/135		
	AC	9	7	1	7	9	7	8	05/22/97	WO	A61K	33/00		
	AD	9	7	2	5	9	8	8	07/24/97	WO	A61K	31/495		
	AE	9	7	3	2	8	5	7	09/12/97	WO	C07D	241/104		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Dray et al. New Pharmacological Strategies for Pain Relief. <u>Annual Review of Pharmacology &amp; Toxicology</u> , 36, pp. 253-280. (1996).
AG	Brasseur. L. Revue des therapeutiques pharmacologiques actuelles de la douleur. <u>Drugs</u> , 53 Suppl 2, pp. 10-17. (1997)
AH	Rang et al. New molecules in analgesia. <u>British Journal of Anesthesia</u> , 75, pp. 145-156 (1995)
AI	Beaver, WT. Combination Analgesics. <u>American Journal of Medicine</u> , 77 (Suppl 3A), pp. 38-53. (1984).
AJ	Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In <u>Evaluation and Treatment of Chronic Pain</u> , 2 <sup>nd</sup> ed., William & Wilkins pp. 363-383. (1992).
AK	Goodman & Gilman's. <u>The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Edition. McGraw-Hill, New York, pp 535 and 551-552.
AL	Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. <u>Pain</u> , 73, 3 pp. 401-406. (1997).
AM	Elches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. <u>Anesthesia &amp; Analgesia</u> , 81 (6), pp. 1175-1180. (1995).
AN	Hodsmen et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. <u>Anaesthesia</u> , 42(9), pp. 1005-1008. (1987).
AO	Kaasalainen et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. <u>Pain</u> , 70, 2-3, pp. 175-183. (1997).
AP	Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. <u>Journal of Clinical Pharmacology</u> , 37 (10), pp. 908-915. (1997).
AQ	Insel. Chapter 27: Analgesic-Antipyretic and Anti-inflammatory Agents. In Hardman, ed., <u>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Edition. McGraw-Hill, New York, pp. 654-655. (1996).
AR	Polisson. Non-steroidal Anti-inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. <u>The American Journal of Medicine</u> , 100 (Suppl 2A), pp. 2A-31S - 2A-36S. (1996).
AS	Vane, J. Towards a better aspirin. <u>Nature</u> , 367, pp. 215-216. (1994).
AT	Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. <u>Journal of Clinical Rheumatology</u> , 2 (3), pp. 135-140. (1996)

EXAMINER

DATE CONSIDERED

6/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FILED

1600 2900

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079US

SERIAL NO.: 09/154,354

10/05/97 632

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: September  
17, 1998

GROUP: 1627

639

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


BA	Van Ryn et al. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. <u>Expert Opinion On Investigational Drugs</u> . pp. 609-614. (1997).
BB	Vane et al. New insights into the mode of action of anti-inflammatory drugs. <u>Inflammation Research</u> . 44, (No.1), pp 1-10 (1995).
BC	Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. <u>British Journal of Rheumatology</u> . 34, Abstract Suppl. 1, p. 48. (1995). Abstract.
BD	Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. <u>Journal of Rheumatology</u> . Vol. 24, Suppl 49, pp. 20-24. (1997).
BE	Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration In Rats. <u>Neuropharmacology</u> Vol. 33, pp. 1609-1611. (1994).
BF	Donnelly et al. COX-II Inhibitors - a new generation of safer NSAIDS? <u>Alimentary Pharmacology and Therapeutics</u> , 11, 2, pp. 227-236. (1997).
BG	Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. <u>Gastroenterology</u> . 112, 3, pp. 1000-1016. (1997).
BH	Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. <u>J Rheumatology</u> , 24, Suppl. 47, pp. 32-39. (1997).
BI	Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Musculoskeletal Disease: A Canadian Consensus. <u>Canadian Medical Association Journal</u> , 155, 1, pp 77-88. (1996).
BJ	Mehlich et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. <u>Journal of Clinical Pharmacology</u> , 37, 9, 863. (1997). Abstract.
BK	Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointestinal Toxicity. <u>Gut</u> , 39, Suppl. 3, A151. (1996). Abstract.
BL	Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). <u>Journal Of Medicinal Chemistry</u> , 40(9), 1347-65. (1997).
BM	Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. <u>Journal Of Rheumatology</u> , 24 Suppl 49, pp. 9-14. (1997).
BN	
BO	
BP	
BQ	
BR	
BS	
BT	

EXAMINER

DATE CONSIDERED

6/29/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



REC  
DEC 6  
TECH CENTER

FORM PTC-1449 (REV. 7-89)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/154,354 <i>101057,432</i>	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: September 17, 1998		GROUP: 1627 <i>639</i>	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
<i>ML</i>	AH	0 7 3 4 2 7 5	11/04/1997	Australia	C07D	261/08	
	AI						
	AJ						
	AK						
	AL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
EXAMINER <i>ML</i>				DATE CONSIDERED <i>6/29/04</i>			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
DEC 1 11 11  
TECH CENTER 1300 2500

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: Not yet known 10/05-7-632	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.		GROUP: Not Yet Known 1639	
				FILING DATE: Herewith			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5 8 5 9 2 5 7	01/12/99	Talley	548	247	08/14/96
	AB	5 8 6 3 8 2 2	01/26/99	Mayer, et al.	514	270	07/02/99
	AC	5 8 4 0 7 3 1	11/24/98	Mayer, et al.	514	289	08/02/95
	AD	5 8 6 9 4 9 8	02/09/99	Mayer, et al.	514	282	07/07/97
	AE	5 8 6 1 4 1 9	01/19/99	Dube, et al.	514	334	07/11/97
	AF	5 7 8 9 4 1 3	08/04/98	Black, et al.	514	255	01/21/97
	AG	5 6 0 4 2 6 0	02/18/97	Guay, et al.	514	605	11/04/93
	AH	5 4 5 8 8 7 9	10/17/95	Singh, et al.	424	400	09/30/94
	AI	5 5 1 6 8 0 3	05/14/96	Raffa	514	570	03/01/95
	AJ	5 8 4 3 4 6 8	12/01/98	Burkoth, et al.	424	448	05/13/96
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AK	Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX-2) By NSAIDs: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Pairet, et al., <i>Inflammopharmacology</i> 4: 61-70, (1996).					
	AL	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. <i>European J. Pharm</i> 355 pp 211-217, (1998).					
	AM	Cyclooxygenases 1 and 2, J.R. Vane, et al. <i>Annu. Rev. Pharmacol. Toxicol.</i> 38: 97-121, (1998).					
	AN	Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. <i>Brain Research</i> 739: 104-110, (1996)					
	AO	Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., <i>Skin Pharmacol. And Applied Skin Phys.</i> 11:273-278, (1998).					
	AP	Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cariona Hay and Jacqueline de Belleruche, <i>Neuro Report</i> 8, 1249-1251, (1997).					
	AQ	The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, <i>Drugs</i> 52 Supp. 5:13-23, (1996).					
	AR	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. <i>Inflamm. Res.</i> 47:79-85, (1998).					
AS	Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, <i>Medicinal Research Reviews</i> , Vol. 16, No. 2, pp. 181-206, (1996).						
EXAMINER 				DATE CONSIDERED 6/29/01			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: Not Yet Known 101057, 632	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: Not Yet Known		GROUP: Not Yet Known 1639	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES      NO
	BL						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
MI	BM	Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. Vol. 12 pp. 1063-1073 (1998).					
	BN	Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With An Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996)					
	BO	Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).					
	BP	Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15, (1996).					
	BQ	Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Visceronoception Induced by Phenylquinone, Hidenobu Kusuvara, et al. Prostaglandins 55: 43-49, (1998).					
2	BR	Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats, D. Dirig, et al. J. Pharmacol. And Experimental Therapeutics Vol. 285, No. 3, pp 1031-1038.					
EXAMINER  M L M				DATE CONSIDERED  6/29/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: Not Yet Known <div style="text-align: right; font-size: 1.2em;">10/057, 632</div>						
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.								
				FILING DATE: Not Yet Known		GROUP: Not Yet Known <div style="text-align: right; font-size: 1.2em;">1639</div>						
<b>U.S. PATENT DOCUMENTS</b>												
*EXAMINER INITIAL	CA	DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	CA											
	CB											
	CC											
	CD											
<b>FOREIGN PATENT DOCUMENTS</b>												
		DOCUMENT NUMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
										YES NO		
	CE	9	9	0	7	4	1	3	2/18/99	WO		
	CF	9	9	3	2	1	1	9	7/1/99	WO		
	CG											
	CH											
	CI											
	CJ											
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>												
	CK	Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. British Journal of Anaesthesia 84 (2) 151-4 (2000).										
	CL	Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. C.S. Wong et al., British Journal of Anaesthesia 85 (5) 747-51 (2000).										
	CM	Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons, M. Melis, et al. Eur. J. Pharmacology 387 (1) R1-R3 (2000).										
	CN	Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX-1 and COX-2 inhibitors in nerve-injured rats, J.M. Lashbrook, et al. Pain 82 (1) 65-72 (1999).										
	CO	Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones, Vaughn et al. British Journal of Pharmacology 123 (8) 1479-81 (1998).										
EXAMINER <div style="text-align: center; font-size: 1.5em;">M L M</div>							DATE CONSIDERED <div style="text-align: center; font-size: 1.5em;">6/29/04</div>					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>												

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CON7

SERIAL NO.: Not Yet Known

10 1057,632

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1239

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
229	DA	5	4	7	4	9	9	5	12/12/95	Ducharme et al.	514	241	01/10/94
	DB	5	6	9	1	3	7	4	11/25/97	Black et al.	514	473	05/18/95
	DC												
	DD												
	DE												
	DF												
	DG												
	DH												
	DI												
	DJ												
	DK												

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	DL													
	DM													
	DN													
	DO													
	DP													

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DQ	
	DR	
	DS	

EXAMINER

M Cell


DATE CONSIDERED

6/29/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: Not Yet Known <b>10/057,632</b>		
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.				
				FILING DATE: Not Yet Known		GROUP: Not Yet Known <b>1639</b>		
<b>U.S. PATENT DOCUMENTS</b>								
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
<b>MC</b>	EA	3 8 0 0 0 4 1	03/26/74	Miller, et al.	424	273	03/02/71	
	EB	4 3 2 2 4 2 7	03/30/82	Buyinski, et al.	424	260	04/16/81	
	EC	4 3 3 8 3 2 4	06/06/82	Gardocki	424	266	03/17/81	
	ED	4 4 0 4 2 1 0	09/13/83	Schmidt	424	260	06/30/82	
	EE	4 4 0 7 8 0 4	10/04/83	Schmidt	424	260	06/30/82	
	EF	4 4 0 7 8 0 5	10/04/83	Schmidt	424	260	06/30/82	
	EG	4 4 6 4 3 7 6	08/07/84	Sunshine, et al.	424	253	10/11/83	
	EH	4 4 8 6 4 3 6	12/04/84	Sunshine, et al.	424	253	03/11/83	
	EL	4 4 8 9 0 8 0	12/18/84	Lomen	424	260	12/06/82	
	<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
<b>MC</b>	EJ	2 0 2 3 3 4 9	02/18/91	Canada	A61K	31/44		
	EK	0 2 7 4 8 4 5	07/20/88	EP (A1)	A61K	31/19		
	EL	0 3 8 8 1 2 5	09/19/90	EP (A1)	A61K	31/485		
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>								
<b>MC</b>	EM	Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. <i>Arzneim-Forsch./Drug Res.</i> 46 (II) 57-63 (1996).						
<b>MC</b>	EN	Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G.K. Vlok, et al. Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg. pp 3-6, (1987).						
	EO							
	EP							
	EO							
	ER							
EXAMINER <b>MC</b>			DATE CONSIDERED <b>6/29/04</b>					
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: Not Yet Known <b>10/057,632</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: Not Yet Known		GROUP: Not Yet Known <b>1639</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>DL</b>	FA	4 5 6 7 1 8 3	01/28/86	Sunshine, et al.	514	264	12/12/83
	FB	4 5 6 9 9 3 7	02/11/86	Baker, et al.	514	282	02/11/83
	FC	4 5 7 1 4 0 0	02/18/86	Arnold	514	282	12/18/84
	FD	4 5 8 7 2 5 2	05/06/86	Arnold	514	282	12/18/84
	FE	4 6 1 9 9 3 4	12/28/86	Sunshine, et al.	514	277	07/08/85
	FF	4 6 9 0 9 2 7	09/01/87	Voss, et al.	514	282	02/03/86
	FG	4 8 3 9 1 7 6	06/13/89	Pahkhanian, et al.	424	465	12/08/87
	FH	4 8 4 4 9 0 7	07/04/89	Elger, et al.	424	465	08/14/86
	FI	4 9 2 7 8 5 4	05/22/90	Sunshine, et al.	514	570	08/21/89
	FJ	5 1 6 4 3 9 8	12/17/92	Sims, et al.	514	282	04/01/91
	FK	5 1 9 0 9 4 7	03/02/93	Riess, et al.	514	282	08/16/91
	<b>DL</b>	FL	5 2 4 0 6 9 4	08/31/93	Gwaltney, Jr.	424	45
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<b>DL</b>  <b>DL</b>	FM	0 0 6 8 8 3 8	06/25/82	EP (A1)	A61K	31/485	
	FN	0 0 6 8 8 3 8	06/25/82	EP (B1)	A61K	31/485	
	FO	2 0 8 1 6 0 4	05/01/95	Canada	A61K	031/135	
	FP						
	FO						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	FR						
	FS						
	FT						
EXAMINER <b>BLM</b>				DATE CONSIDERED <b>4/29/04</b>			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CON7

SERIAL NO.: Not Yet Known

10/057,632

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1639

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ML	GA	5	4	0	9	9	4	4	04/25/95	Black, et al.	514	359	03/12/93
	GB	5	4	3	6	2	6	5	06/25/95	Black, et al.	514	420	11/12/93
	GC	5	5	1	0	3	6	8	04/23/96	Lau, et al.	514	419	05/22/95
	GD	5	5	2	1	2	1	3	05/28/96	Prasit, et al.	514	443	08/29/94
	GE	5	5	5	0	1	4	2	08/27/96	Ducharme et al.	514	365	05/08/95
	GF	5	5	5	2	4	2	2	09/03/96	Gauthier, et al.	514	368	01/11/95
	GG	5	6	0	4	2	5	3	02/18/97	Lau, et al.	514	415	05/22/95
ML	GH	5	6	3	9	7	8	0	06/17/97	Lau, et al.	514	419	05/22/95

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GI													
	GJ													
	GK													
	GL													
	GM													

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ML	GN	Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, Supplement 2 (1998).
	GO	
	GP	
	GQ	
	GR	

EXAMINER

*ML*

DATE CONSIDERED

4/6/94

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON7		SERIAL NO.: Not Yet Known <b>161057, 632</b>	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: Not Yet Known		GROUP: Not Yet Known <b>1639</b>	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HD						
	HE						
	HF						
	HG						
	HH						
	HI						
	HJ						
	HK						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	HL						
	HM						
	HN						
	HO						
	HP						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
<i>OK</i>	HQ	Rorarius et al., "Non-Steroidal Anti-Inflammatory Drugs for PostOperative Pain Relief," Curr. Opin. In Anaesthesiology, 7, 358-362). (1994)					
	HR	Hanses et al. "Pharmacokinetics and Drug input Characteristics for a Disclotenac-Codeine Phosphate Combination Following Oral and Rectal Administration," Arzneim.-Forsch./Drug Res., 46(II), Nr. 1, 57-63. (1996)					
	HS	Merck Index, Twelfth Edition, Merck & Co. Publishers, page 1194. (1996)					
<i>OK</i>	HT	Goodman and Gillman's: Pharmaceutical Basis of Therapeutics, "Chapter 22: Opioid Analgesics and Antagonists", MacMillan Publishing Co., Inc., pp-494-497, esp. Table 22-1, p. 496. (1980)					
EXAMINER  <i>M L N</i>				DATE CONSIDERED  <i>6/29/04</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							